Pipeline Progress at Corcept - Analyst Blog
December 16 2013 - 5:05PM
Zacks
Corcept Therapeutics Inc.'s (CORT) key
objective in 2014 is the successful commercialization of its only
approved product, Korlym.
Corcept launched Korlym in the U.S in Apr 2012. Korlym is
approved in the U.S. and the EU as a once-daily oral medication for
the treatment of hyperglycemia secondary to hypercortisolism in
adults suffering from endogenous Cushing’s syndrome, who have type
II diabetes or glucose intolerance.
We remind investors that Corcept enjoys orphan drug designation
for Korlym from the U.S. Food and Drug Administration (FDA) for the
approved indication.
Corcept recently announced plans to extend its development
program for glucocorticoid receptor (GR) antagonists, including
Korlym, into oncology. The company plans to expand its development
program based on encouraging early clinical and pre-clinical data
from leading academic institutions including the University of
Chicago.
The data shows the efficacy of cortisol, a glucocorticoid stress
hormone, and its receptors in chemotherapy resistance, particularly
for women suffering from relapsed, metastatic triple-negative
breast cancer (TNBC), a form of the disease with a poor
prognosis.
We note that Corcept has licensed patent rights from the
University of Chicago's Center for Technology Development &
Ventures, for the use of GR antagonists in combination with
chemotherapy in the treatment of estrogen-receptor-negative breast
cancer, a form of cancer that includes TNBC.
Based on positive data from the studies conducted by the
University of Chicago, Corcept has filed an investigational new
drug (IND) application with the FDA. Corcept also plans to conduct
its own multi-center, phase I clinical study of Korlym in
combination with Eisai Co., Ltd.'s (ESALY)
Halaven.
We are encouraged by the company’s efforts to commercialize
Korlym and develop it for additional indications.
Corcept currently carries a Zacks Rank #3 (Hold). Right now,
Shire (SHPG) and Forest
Laboratories (FRX) look attractive. Both carry a Zacks
Rank #1 (Strong Buy).
CORCEPT THERAPT (CORT): Free Stock Analysis Report
EISAI CO LTD (ESALY): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024